Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare TSE:ARZCVE:MMYCVE:SCATSE:YRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARZAralez PharmaceuticalsC$0.00C$0.29▼C$3.72C$28.89MN/A79,103 shs274,400 shsMMYMonument MiningC$0.49-4.9%C$0.42C$0.13▼C$0.51C$112.00M1.07371,011 shs398,501 shsSCASavary GoldC$0.12-4.2%C$0.12C$0.04▼C$0.13C$29.40MN/A830,838 shs204,500 shsYRBYorbeau ResourcesC$0.04+14.3%C$0.04C$0.03▼C$0.06C$18.46M1.46216,200 shs635,000 shsA Beginner's Guide to Investing in CannabisUnlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARZAralez Pharmaceuticals0.00%0.00%0.00%0.00%0.00%MMYMonument Mining0.00%+15.91%+14.61%+37.84%+200.00%SCASavary Gold0.00%0.00%0.00%0.00%0.00%YRBYorbeau Resources0.00%+14.29%+14.29%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARZAralez PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMMYMonument Mining2.8608 of 5 stars3.50.01.70.01.71.71.3SCASavary GoldN/AN/AN/AN/AN/AN/AN/AN/AYRBYorbeau ResourcesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARZAralez Pharmaceuticals 0.00N/AN/AN/AMMYMonument Mining 3.00BuyC$0.6840.21% UpsideSCASavary Gold 0.00N/AN/AN/AYRBYorbeau Resources 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest YRB, SCA, ARZ, and MMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/18/2025MMYMonument MiningFundamental ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuyC$0.68(Data available from 5/12/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARZAralez PharmaceuticalsN/AN/AN/AN/AN/AN/AMMYMonument MiningC$44.94M2.49C$0.34 per share1.43C$0.38 per share1.28SCASavary GoldN/AN/AC$0.01 per share14.38C$0.05 per shareN/AYRBYorbeau ResourcesC$723.01K25.54C$0.00 per share12.50C$0.05 per share0.80Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARZAralez PharmaceuticalsN/AN/A0.00N/AN/AN/AN/AN/AN/AMMYMonument MiningC$6.70MC$0.0411.75∞N/A14.91%8.04%6.37%N/ASCASavary GoldN/A-C$0.00N/A∞N/AN/AN/AN/AN/AYRBYorbeau Resources-C$2.34MN/AN/A∞N/AN/A-9.36%-5.92%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARZAralez PharmaceuticalsN/AN/AN/AN/AN/AMMYMonument MiningN/A24.39%N/AN/AN/ASCASavary GoldN/AN/AN/AN/AN/AYRBYorbeau ResourcesN/A2.03%N/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARZAralez PharmaceuticalsN/AN/AN/AMMYMonument Mining0.122.702.36SCASavary GoldN/A10.0610.04YRBYorbeau Resources3.860.142.58Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARZAralez PharmaceuticalsN/AMMYMonument Mining1.21%SCASavary GoldN/AYRBYorbeau ResourcesN/AInsider OwnershipCompanyInsider OwnershipARZAralez PharmaceuticalsN/AMMYMonument Mining18.37%SCASavary GoldN/AYRBYorbeau Resources28.11%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARZAralez Pharmaceuticals4,50067.19 millionN/ANot OptionableMMYMonument Mining39,500230.93 millionN/ANot OptionableSCASavary Gold1,228255.63 millionN/ANot OptionableYRBYorbeau Resources5461.59 millionN/ANot OptionableYRB, SCA, ARZ, and MMY HeadlinesRecent News About These CompaniesYorbeau Resources Full Year 2024 Earnings: EPS: CA$0.018 (vs CA$0.006 loss in FY 2023)March 30, 2025 | uk.finance.yahoo.comYorbeau Resources Launches 2025 Exploration Program in QuébecJanuary 22, 2025 | tipranks.comYorbeau Resources Begins an Exploration Program on Its Beschefer Property in Northwestern QuébecJanuary 22, 2025 | financialpost.comYorbeau Resources Begins an Exploration Program on Its Beschefer Property in Northwestern QuébecJanuary 22, 2025 | financialpost.comYorbeau Finalizes Sale of Rouyn PropertyDecember 16, 2024 | tipranks.comYorbeau Completes Sale of Rouyn PropertyDecember 16, 2024 | financialpost.comInsider Buying: Yorbeau Resources Inc. (TSE:YRB) Director Buys 350,000 Shares of StockOctober 31, 2024 | insidertrades.comYRB:CA Yorbeau Resources Inc.October 25, 2024 | seekingalpha.comAcquisition of Common Shares of Yorbeau Resources Inc. by Henri Gélinas, ChairmanOctober 25, 2024 | finance.yahoo.comYorbeau Chairman Increases Stake with Share AcquisitionOctober 25, 2024 | markets.businessinsider.comYorbeau Resources Inc. (TSE:YRB) Director Purchases C$54,000.00 in StockOctober 25, 2024 | insidertrades.comYorbeau sells Rouyn property to Australian investorsOctober 3, 2024 | miningweekly.comYorbeau Resources Signs Agreement to Sell the Rouyn Property to Australian InvestorsOctober 2, 2024 | juniorminingnetwork.comYorbeau Signs Agreement to Sell the Rouyn Property to Australian InvestorsOctober 2, 2024 | markets.businessinsider.comYorbeau Resources sells Rouyn gold project for $25MOctober 2, 2024 | canadianminingjournal.comYorbeau Resources Second Quarter 2024 Earnings: CA$0.001 loss per share (vs CA$0.001 loss in 2Q 2023)August 16, 2024 | finance.yahoo.comYorbeau Closes Non-Brokered Private PlacementAugust 7, 2024 | goldseiten.deClosing Bell: Yorbeau Resources Inc up on Friday (YRB)July 23, 2024 | theglobeandmail.comYorbeau Consolidates Interest in Its Beschefer PropertyMay 28, 2024 | finance.yahoo.comClosing Bell: Yorbeau Resources Inc down on Thursday (YRB)May 24, 2024 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesBroadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostBy Leo Miller | May 7, 2025View Broadcom Stock Gets a Lift on Hyperscaler Earnings & CapEx BoostApplied Digital: AI Data Center Hype or Real Value?By Jea Yu | April 21, 2025View Applied Digital: AI Data Center Hype or Real Value?3 Stocks to Buy Now for Tariff ImmunityBy Gabriel Osorio-Mazilli | April 23, 2025View 3 Stocks to Buy Now for Tariff ImmunityWhy Uber’s Stock Could Soar on AV Growth and Tariff ResilienceBy Jea Yu | April 16, 2025View Why Uber’s Stock Could Soar on AV Growth and Tariff ResilienceDisney: The Compelling Case for Buying Now Before They Scale UpBy Jea Yu | April 29, 2025View Disney: The Compelling Case for Buying Now Before They Scale UpYRB, SCA, ARZ, and MMY Company DescriptionsAralez Pharmaceuticals TSE:ARZAralez Pharmaceuticals Inc. operates as a specialty pharmaceutical company in the United States and Canada. It engages in acquiring, developing, and commercializing products in the areas of cardiovascular, pain management, dermatological allergy, and other indications. It offers Zontivity for the reduction of thrombotic cardiovascular events in patients with heart attack or peripheral arterial disease; Toprol-XL, a cardioselective beta-blocker that is indicated for the treatment of hypertension; Fibricor, a fenofibric acid for the treatment of severe hypertriglyceridemia and patients with primary hypercholesterolemia or mixed dyslipidemia; and Blexten, an antihistamine drug for the symptomatic relief of allergic rhinitis and chronic spontaneous urticarial. The company also markets Cambia, a non-steroidal anti-inflammatory drug (NSAID) for the acute treatment of migraine attacks; Soriatane for the treatment of severe psoriasis and other disorders of keratinization; Proferrin, an iron supplement; Fiorinal and Fiorinal C for the relief of tension type headaches; and Bezalip SR, a pan-peroxisome proliferator-activated receptor activator to treat hyperlipidemia, as well as to increase insulin sensitivity and decrease blood glucose levels for the patients with metabolic syndrome. In addition, it provides out-licensed products, which include VIMOVO for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, as well as to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers; and Treximet, a migraine medicine. The company was incorporated in 2015 and is headquartered in Mississauga, Canada.Monument Mining CVE:MMYC$0.48 -0.03 (-4.90%) As of 03:43 PM EasternMonument Mining Limited operates as a gold producer, engages in the acquisition, exploration, and development of gold, precious metals, and other base metal properties in Canada, Australia, and Malaysia. The company holds 100% interest in the Selinsing gold mine, including the Selinsing, Buffalo Reef, Felda Land, and Famehub projects that are located in Pahang State within the Central Gold Belt of Western Malaysia; and the Murchison gold project portfolio comprising the Burnakura, Tuckanarra, and Gabanintha projects, which are located in the Murchison region of Western Australia. The company is headquartered in Vancouver, Canada.Savary Gold CVE:SCAC$0.12 -0.01 (-4.17%) As of 05/2/2019Savary Gold Corp. engages in the exploration and evaluation of gold properties in West Africa. Its principal project is the Karankasso project that consists of five exploration licenses covering a total area of 688 square kilometers located in the Houndé Gold Belt in Burkina Faso. The company was formerly known as Savary Capital Corp. and changed its name to Savary Gold Corp. in September 2012. Savary Gold Corp. was incorporated in 2008 and is headquartered in Toronto, Canada.Yorbeau Resources TSE:YRBC$0.04 +0.01 (+14.29%) As of 05/9/2025 01:10 PM EasternYorbeau Resources Inc is involved in the exploration of mineral properties in the Province of Quebec. The company's project includes Rouyn Ellison, Beschefer, Scott Lake and many more. The operating segment of the company is Mining Exploration. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs 5 Reasons the Rebound in Microchip Technology Stock Is Real Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
